

Figure 5. A: IGFBP-2 mRNA expression was measured by real-time RT-PCR in 24 pairs of human normal and corresponding tumor tissue. The mRNA levels of IGFBP-2 are presented as arbitrary units for the mRNA levels of human $\beta 2$ microglobulin (B2M). A paired t-test was used for statistical significance ($^*P$ = 0.021). **B:** Representative picture of Western blots. IGFBP-2 protein levels were measured with four pairs of normal (N) and corresponding tumor (T) tissue from lung adenocarcinoma patients.

cer. Caspases are cysteine proteases that play essential roles in mammalian apoptosis. Procaspase-3 cleavage and consequent activation is the final step of caspase cascades in response to various apoptotic stimuli. Several authors have proved that enforced procaspase-3 potentiates sensitivity to chemotherapy and promotes apoptosis.[40–42] In lung cancer, decreased caspase-3 expression has been shown as a poorer prognostic factor in non-small-cell lung cancer.[43–45]

Our results raise the important question regarding the regulatory mechanisms involved in caspase-3 inhibition via IGFBP-2. A recent report has shown that transcriptional factor Sp1 activates the caspase-3 promoter.[46] Mammalian IGFBP-2 also has the Sp1 binding regions upstream of the transcriptional start site.[47] One possible explanation for the regulation of caspase-3 via IGFBP-2 is that IGFBP-2 overexpression in cancer cells inhibits Sp1 through negative feedback mechanism, and thereby inhibits caspase-3 gene and protein expression. Another possibility is PTEN. IGFBP-2 has been identified as the most significant molecular signature for loss of PTEN in brain and prostate cancer.[30] It has been shown that PTEN is cleaved by caspase-3 in a PTEN phosphorylation-regulated manner.[48] IGFBP-2 overexpression may induce PTEN up-regulation and protein stabilization through feedback mechanisms, and thereby negatively regulating caspase-3 activation. Future studies will help to identify the precise regulatory mechanism of caspase-3 mediated by IGFBP-2. Recent studies demonstrate caspase-3 has apoptosis-independent physiological functions, including differentiation, maturation, proliferation, and immuno response.[49,50] Thus, caspase-3 may contribute to lung cancer development and progression by multiple functions including apoptosis.



Figure 6. A: Representative pictures of immunohistochemistry for IGFBP-2 in lung adenocarcinomas. Note a strong immunoreactivity in cytoplasm of cancer cells, whereas almost negligible in normal epithelium (**arrowheads**). **B:** Typical membraneous IGFBP-2 expression. **C:** IGFBP-2 expression is gradually increased from benign cells (**arrows**) to malignant cells (**arrowheads**). **D:** Strong IGFBP-2 expression is only localized in cancer cells with high nuclear grade. **E:** Representative mutually exclusive expression between IGFBP-2 (**left, arrowheads**) and procaspase-3 (**right, arrowheads**) in serial sections on tissue microarray. **F:** Another case also demonstrates an inverse expression pattern between IGFBP-2 (**left**) and procaspase-3 (**right**) in serial sections. Original magnification: ×400 (**A–D**, and **F**); ×100 (**E**).

Because IGF signaling was not altered by the overexpression of intracellular IGFBP-2, our data suggest that intracellular and secreted IGFBP-2 are functionally independent. Interestingly, IGFBP-5 is another cancer-associated IGFBP, and it has been reported that intracellular IGFBP-5 induces growth inhibition and caspase-dependent apoptosis of breast cancer cells, whereas adding secreted-IGFBP-5 was not internalized and had no effects on growth and apoptosis.[51] Further, endogenous and exogenous IGFBP-5 is suggested to exhibit opposing actions on cell survival in osteosarcoma cells.[52] IGFBP-3, a most major IGFBP in serum, also induces

Table 1. Inverse Relationship between IGFBP-2 and Caspase-3 Expression in 169 Cases of Lung Adenocarcinomas

	Caspase-3		
IGFBP-2	Weak	Moderate	Strong
Weak	48	20	10
Moderate	40	9	2
Strong	40	0	0

Fisher's exact test was used for statistical significance (P = 0.0002). Data represent the number of patients.

growth inhibition and apoptosis in cancer cells, but it does not require the cell surface binding and nuclear translocation of IGFBP-3 in breast and prostate cancer.[53,54] These lines of evidence prompt us to propose that intracellular IGFBP-2 elicits antiapoptosis effects on cancer cells via intracrine mechanism, independent of secreted IGFBP-2. Although not yet identified in IGFBP-2, the posttranslational modification (ie, glycosylation) of secreted IGFBP-3 or -5 can be involved in the functional difference between intracellular and secreted form.[51]

There are a number of lines of evidence that IGFBP-3 is able to induce apoptosis and potentiate the apoptotic effects of UV or chemotherapy.[55,56] The inverse relationship between IGFBP-2 and IGFBP-3 expression at tissue and serum levels in a variety of cancers, including prostate,[31,55,57] ovarian,[58] and testicular cancer, has been well recognized.[59] We also found a relatively inverse relationship between secreted levels of IGFBP-2 and IGFBP-3 in lung adenocarcinoma cell lines (unpublished data). Remarkably, IGFBP-2 is predominantly expressed in cytoplasm and nucleus of lung epithelium when exposed to hyperoxia, whereas IGFBP-3 is localized in the extracellular compartment.[60] These findings suggest that IGFBP-2 and -3 may be differentially regulated and also exert a distinct action for cell proliferation and apoptosis in different compartments.

Our immunohistochemical analysis demonstrated that most adenocarcinomas revealed a cytoplasmic IGFBP-2 expression pattern, and a significant inverse association between IGFBP-2 and procaspase-3 expression. These results support the evidence that intracellular IGFBP-2 regulates procaspase-3 expression *in vitro*, thereby inhibiting apoptosis. Interestingly, IGFBP-2 expression showed a marked heterogeneity within lung adenocarcinoma tissue. At cellular levels, a strong IGFBP-2 expression was found in cancer cells having high nuclear grade. This finding suggests IGFBP-2 overexpression in cancer cells is caused by adaptive mechanisms in tumor microenvironment and confers aggressive biological nature to survive under the toxic conditions.

IGFBP-2 protein is degraded by proteases such as matrix metalloprotease-1 and -7, calpain, as well as by basic fibroblast growth factor and an androgen blockade.[61–64] We found IGFBP-2 protein was degraded by a treatment of PI3K inhibitor in A549 cells. Because a various new PI3K inhibitors have been entered clinical trials,[65] IGFBP-2 would be a useful biomarker for the treatment with PI3K inhibitors in lung cancer as well as in glioma, prostate, and breast cancers.[30,66] Further, our results suggested that IGFBP-2 is a therapeutic target in lung cancer, in line with the results in breast and ovarian cancers.[6,10] In general, lung adenocarcinomas typically showed a resistance to multiple cancer chemotherapy. Because cytoplasmic IGFBP-2 may provide cancer cells with an antiapoptotic ability, IGFBP-2 is an attractive therapeutic target especially for chemotherapy resistant tumors. The combination of chemotherapy and the IGFBP-2 or PI3K inhibitors may also potentiate drug-sensitivity.

Lung cancer is the leading cause of cancer death worldwide. Despite the availability of some cytotoxins and molecular target therapy, the efficacy of these agents is limited. It has thus become increasingly necessary to identify novel approaches to treat lung cancer. We propose that IGFBP-2 is not only a useful biomarker for predicting chemotherapy response, but also a novel therapeutic target in lung cancer.

Acknowledgments

We thank Ms. Tomoyo Kakita, Ms. Mayumi Ogawa, and Mr. Hironori Murayama for their excellent technical assistance, and Dr. Hiroaki Kataoka for IGFBP-2 constructs. We also thank Dr. Farid Gizatullin for helpful discussion.

References

1. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW, Rossjohn J, Price JT: Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 2004, 64:977–984
2. Wang GK, Hu L, Fuller GN, Zhang W: An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem 2006, 281:14085–14091
3. Russo VC, Bach LA, Fosang AJ, Baker NL, Werther GA: Insulin-like growth factor binding protein-2 binds to cell surface proteoglycans in the rat brain olfactory bulb. Endocrinology 1997, 138:4858–4867
4. Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW: Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004, 32:859–868
5. Firth SM, Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002, 23:824–854
6. So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M: Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 2008, 14:6944–6954
7. Wang H, Wang H, Shen W, Huang H, Hu L, Ramdas L, Zhou YH, Liao WS, Fuller GN, Zhang W: Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 2003, 63:4315–4321
8. Miyake H, Hara I, Yamanaka K, Muramaki M, Gleave M, Eto H: Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep 2005, 13:341–345
9. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME: Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003, 63:3575–3584
10. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemisto A, Kavanagh JJ, Lee JH, Zhang W: Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 2005, 4:7
11. Hoeflich A, Fettscher O, Lahm H, Blum WF, Kolb HJ, Engelhardt D, Wolf E, Weber MM: Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res 2000, 60:834–838
12. Diehl D, Hessel E, Oesterle D, Renner-Muller I, Elmlinger M, Langhammer M, Gottlicher M, Wolf E, Lahm H, Hoeflich A: IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer 2009, 124:2220–2225
13. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, Zhang W: Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA: 2007, 104:11736–11741
14. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E: Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001, 61:8601–8610
15. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK, Zhang W: Reactivation of insulin-like growth factor binding pro-

tein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 1999, 59:4228–4232
16. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993, 77:229–233
17. Lee DY, Kim SJ, Lee YC: Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 1999, 14:401–404
18. Yazawa T, Sato H, Shimoyamada H, Okudela K, Woo T, Tajiri M, Ogura T, Ogawa N, Suzuki T, Mitsui H, Ishii J, Miyata C, Sakaeda M, Goto K, Kashiwagi K, Masuda M, Takahashi T, Kitamura H: Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. Am J Pathol 2009, 175:976–987
19. Sato H, Yazawa T, Suzuki T, Shimoyamada H, Okudela K, Ikeda M, Hamada K, Yamada-Okabe H, Yao M, Kubota Y, Takahashi T, Kamma H, Kitamura H: Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia. Am J Pathol 2006, 169:1550–1566
20. el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G: Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 1994, 57:491–497
21. Karasik A, Menczer J, Pariente C, Kanety H: Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994, 78:271–276
22. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y: Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1998, 83:1713–1720
23. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, Busch C, Stalsberg H: Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 2005, 58:361–366
24. Mohnike KL, Kluba U, Mittler U, Aumann V, Vorwerk P, Blum WF: Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia. Eur J Pediatr 1996, 155:81–86
25. DeGraff DJ, Aguiar AA, Sikes RA: Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res 2009, 1:115–130
26. Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y: ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008, 68:8547–8554
27. Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H: Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 2007, 282:18634–18644
28. Rajaram S, Baylink DJ, Mohan S: Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997, 18:801–831
29. Kaaks R, Lukanova A: Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001, 60:91–106
30. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL: Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 2007, 104:5563–5568
31. Blum WF, Horn N, Kratzsch J, Jorgensen JO, Juul A, Teale D, Mohnike K, Ranke MB: Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regul 1993, 3:100–104
32. Reeve JG, Morgan J, Schwander J, Bleehen NM: Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 1993, 53:4680–4685
33. Grimberg A, Coleman CM, Shi Z, Burns TF, MacLachlan TK, Wang W, El-Deiry WS: Insulin-like growth factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol Ther 2006, 5:1408–1414
34. Lukanova A, Toniolo P, Akhmedkhanov A, Biessy C, Haley NJ, Shore RE, Riboli E, Rinaldi S, Kaaks R: A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. Int J Cancer 2001, 92:888–892
35. Kuang Z, Yao S, Keizer DW, Wang CC, Bach LA, Forbes BE, Wallace JC, Norton RS: Structure, dynamics and heparin binding of the C-terminal domain of insulin-like growth factor-binding protein-2 (IGFBP-2). J Mol Biol 2006, 364:690–704
36. Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P: Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 2003, 105:14–19
37. Baron-Hay S, Boyle F, Ferrier A, Scott C: Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 2004, 10:1796–1806
38. Vorwerk P, Mohnike K, Wex H, Rohl FW, Zimmermann M, Blum WF, Mittler U: Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab 2005, 90:3022–3027
39. Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiaer U, Espelund U, Jepsen JS: Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res 2006, 16:224–239
40. Miyoshi N, Naniwa K, Kumagai T, Uchida K, Osawa T, Nakamura Y: Alpha-tocopherol-mediated caspase-3 up-regulation enhances susceptibility to apoptotic stimuli. Biochem Biophys Res Commun 2005, 334:466–473
41. Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD: Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 2001, 61:348–354
42. Friedrich K, Wieder T, Von Haefen C, Radetzki S, Janicke R, Schulze-Osthoff K, Dorken B, Daniel PT: Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 2001, 20:2749–2760
43. Saad AG, Yeap BY, Thunnissen FB, Pinkus GS, Pinkus JL, Loda M, Sugarbaker DJ, Johnson BE, Chirieac LR: Immunohistochemical markers associated with brain metastases in patients with non-small-cell lung carcinoma. Cancer 2008, 113:2129–2138
44. Yoo J, Jung JH, Lee MA, Seo KJ, Shim BY, Kim SH, Cho DG, Ahn MI, Kim CH, Cho KD, Kang SJ, Kim HK: Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci 2007, 22:318–325
45. Koomagi R, Volm M: Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer. Anticancer Res 2000, 20:493–496
46. Sudhakar C, Jain N, Swarup G: Sp1-like sequences mediate human caspase-3 promoter activation by p73 and cisplatin. Febs J 2008, 275:2200–2213
47. Kutoh E, Margot JB, Schwander J: Identification and characterization of the putative retinoblastoma control element of the rat insulin-like growth factor binding protein-2 gene. Cancer Lett 1999, 136:187–194
48. Torres J, Rodriguez J, Myers MP, Valiente M, Graves JD, Tonks NK, Pulido R: Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J Biol Chem 2003, 278:30652–30660
49. Kuranaga E, Miura M: Nonapoptotic functions of caspases: caspases as regulatory molecules for immunity and cell-fate determination. Trends Cell Biol 2007, 17:135–144
50. Nhan TQ, Liles WC, Schwartz SM: Physiological functions of caspases beyond cell death. Am J Pathol 2006, 169:729–737
51. Butt AJ, Dickson KA, McDougall F, Baxter RC: Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 2003, 278:29676–29685
52. Yin P, Xu Q, Duan C: Paradoxical actions of endogenous and exogenous insulin-like growth factor-binding protein-5 revealed by RNA interference analysis. J Biol Chem 2004, 279:32660–32666
53. Bhattacharyya N, Pechhold K, Shahjee H, Zappala G, Elbi C, Raaka B, Wiench M, Hong J, Rechler MM: Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J Biol Chem 2006, 281:24588–24601
54. Butt AJ, Fraley KA, Firth SM, Baxter RC: IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. Endocrinology 2002, 143:2693–2699
55. Nickerson T, Huynh H, Pollak M: Insulin-like growth factor binding

protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun 1997, 237:690–693

56. Rajah R, Valentinis B, Cohen P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997, 272:12181–12188
57. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR: Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996, 81:411–420
58. Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS: Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 *in epithelial ovarian cancer: correlation with cancer antigen* 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 1997, 82:2308–2313
59. Fottner C, Sattarova S, Hoffmann K, Spottl G, Weber MM: Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers alpha-fetoprotein and human chorionic gonadotropin. Eur J Endocrinol 2008, 159:317–327
60. Besnard V, Corroyer S, Trugnan G, Chadelat K, Nabeyrat E, Cazals V, Clement A: Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells. Biochim Biophys Acta 2001, 1538:47–58
61. Berg U, Bang P, Carlsson-Skwirut C: Calpain proteolysis of insulin-like growth factor binding protein (IGFBP) -2 and -3, but not of IGFBP-1. Biol Chem 2007, 388:859–863
62. Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A: Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun 2005, 333:1011–1016
63. DeGraff DJ, Malik M, Chen Q, Miyako K, Rejto L, Aguiar AA, Bancroft DR, Cohen P, Sikes RA: Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model. J Cell Physiol 2007, 213:261–268
64. Russo VC, Rekaris G, Baker NL, Bach LA, Werther GA: Basic fibroblast growth factor induces proteolysis of secreted and cell membrane-associated insulin-like growth factor binding protein-2 in human neuroblastoma cells. Endocrinology 1999, 140:3082–3090
65. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P: Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008, 8:393–412
66. Martin JL, Baxter RC: Expression of insulin-like growth factor binding *protein-2* by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology 2007, 148:2532–2541

Lung Cancer 70 (2010) 94–102



Contents lists available at ScienceDirect

Lung Cancer

journal homepage: www.elsevier.com/locate/lungcan



Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of *KRAS* and *EGFR* mutations

Miyako Hiramatsu[a,b], Hironori Ninomiya[a], Kentaro Inamura[a], Kimie Nomura[a], Kengo Takeuchi[a], Yukitoshi Satoh[a,d], Sakae Okumura[d], Ken Nakagawa[d], Takao Yamori[c], Masaaki Matsuura[e], Toshiaki Morikawa[b], Yuichi Ishikawa[a,*]

[a] *Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan*
[b] *Department of Thoracic Surgery, Tokyo Jikei University of Medicine, Japan*
[c] *Division of Molecular Pharmacology, The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research (JFCR), Japan*
[d] *Department of Thoracic Surgical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR), Japan*
[e] *Division of Cancer Genomics, The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Japan*

ARTICLE INFO

Article history:
Received 16 September 2009
Received in revised form 2 December 2009
Accepted 5 January 2010

Keywords:
Lung adenocarcinoma
Receptor tyrosine kinases
Survival
Akt
TTF-1
Signal pathway

ABSTRACT

The activation status of signal transduction pathways involving receptor tyrosine kinases and its association with *EGFR* or *KRAS* mutations have been widely studied using cancer cell lines, although it is still uncertain in primary tumors.

To study the activation status of main components of growth factor-induced pathways, phosphorylated Akt (pAkt), extracellular signal-regulated kinases 1 and 2 (pERK) and other downstream proteins were immunohistochemically examined using surgical samples of 193 primary lung adenocarcinomas. Also, thyroid transcription factor-1 (TTF-1) expression and mutation status of *EGFR* and *KRAS* were examined.

Advanced tumor stages ($p < 0.001$), negative TTF-1 expression ($p < 0.001$) and Akt activation ($p = 0.015$) were independent and significant poor prognostic markers. Akt activation related to advanced stage ($p = 0.021$), invasiveness ($p = 0.004$), and not to mutations. TTF-1 expression associated with never-smoker ($p = 0.013$), pre- or minimally invasiveness ($p < 0.001$) and *EGFR* mutations ($p = 0.017$) as well as with pERK ($p = 0.039$) expression. *EGFR* mutations did not correlated with pAkt and pERK expression, which was different from the results based on cultured cells, while *KRAS* mutations were solely and significantly linked to ERK activation ($p = 0.009$).

In lung adenocarcinoma, tumors with TTF-1 expression have distinct characteristics regarding mutations, signal protein activation and clinical issues. Moreover, this property was revealed to be important in outcome estimation at any tumor stage, whereas Akt activation is abnormally affected according to the tumor stage regardless of their cell origin. The signal proteins were differently related to mutation status from cultured cells.

© 2010 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Lung cancer is one of the leading causes of cancer-related deaths worldwide [1] and adenocarcinoma is recently becoming a frequent histologic type among non-small-cell lung cancers (NSCLCs) in many countries. Gefitinib, an inhibitor of epidermal growth factor receptor (*EGFR*) tyrosine kinase, has shown remarkable efficacy for control of a subset of lung adenocarcinomas, reflecting improved understanding of the underlying biology [2]. Especially the detection of somatic mutations in *EGFR* shed light on the mechanisms of acquisition of tumor growth advantage, featuring dysregulated signal transduction in tumor cells [3,4].

Akt, a serine/threonine kinase, and extracellular signal-regulated kinases 1 and 2 (ERK) are major target proteins, downstream of EGFR and various other oncoproteins such as Ras and Raf. They are known to be activated in a wide spectrum of human cancer together with various downstream substrates such as glycogen synthase kinase 3-beta (GSK3B), mammalian target of Rapamycin (mTOR), p70 ribosomal protein S6 kinase (S6K) and forkhead proteins FKHR/FKHRL1 (FKHR) [5–8] and to play central roles in tumorigenesis or cell proliferation. The present study was performed to elucidate, by immunohistochemistry (IHC), whether there might be selective activation of downstream pathways of receptor tyrosine kinases (RTKs) in lung adenocarcinomas, depending on tumor-cell lineage or with/without *EGFR* and *KRAS* mutations. We further evaluated the clinicopathological and prognostic significance of such activation in various adenocarcinoma subtypes. Since we earlier revealed by expression profiling that

* Corresponding author. Tel.: +81 3 3570 0448; fax: +81 3 3570 0558.
E-mail address: ishikawa@jfcr.or.jp (Y. Ishikawa).

0169-5002/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.lungcan.2010.01.001

adenocarcinoma cell lines might have different characteristics of gene expression from clinical adenocarcinomas [9], we here used tissue materials of surgically resected adenocarcinomas rather than cell lines.

2. Materials and methods

2.1. Patients and pathological review

A series of 193 Japanese cases with primary lung adenocarcinoma surgically resected between 1998 and 2001 at the Department of Thoracic Surgical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR), Tokyo, were selected for the present study. Informed consent was obtained from all the subjects at the time of surgery. This study was approved by the Institutional Review Board of the JFCR. All patients were staged pathologically according to the 5th edition of the UICC-TNM staging system [10]. For accuracy of survival analysis, only death of lung cancer was counted as cause-specific death. Smoking history was ascertained with all patients in detail.

Histological diagnosis was made according to the WHO classification [11], using sections through the largest cut surface of each tumor stained by hematoxylin–eosin and alcian-blue methods and PAS reaction. However, with its subdivision of lung adenocarcinomas, more than 80% tumors fell into the mixed subtype category. We therefore additionally used an noninvasive/invasive dichotomy as well as a predominance classification for invasive carcinomas, which is mostly based on the WHO classification except for the mixed subtype, such as bronchioloalveolar carcinoma (BAC) predominant, papillary predominant, acinar predominant, etc. The noninvasive carcinoma includes BAC. In the predominance classification of invasive carcinomas, we diagnosed by a component that makes up the predominant portion in the largest cut surface, or the cut surface containing a solid part shown by CT scans, of a tumor. Also, we employed a concept of "minimally invasive adenocarcinomas", which were defined to be lesions where an invasive area of less than 5 mm in diameter or less.

2.2. Tissue microarrays

Tumor tissues were fixed in 15% neutral formalin and embedded in paraffin. Three histologically representative sites were selected per tumor, considering the well-known heterogeneity of lung adenocarcinomas (including the peripheral boundary and the central part of each tumor) and tissue microarrays were constructed as follows. Selected points of the donor paraffin blocks of the largest cut surface were punched with a 2-mm-diameter coring needle, and transferred to the array in the recipient block using a manual tissue arrayer (KIN-1, Azumaya, Inc, Japan). 48 human tissue rods (16 tumors) were embedded in one tissue array block. Based on our preliminary examinations using whole sections of tumor for several cases, we adopted 2 mm needles and three points to take tissues, rather than smaller needles and only one or two points. As controls, 3 mouse xenografts were selected from the panel of 39 cell lines (termed JFCR 39) [12] and embedded together with clinical samples in each array block as detailed below.

2.3. Protein expression analysis

Phosphorylated protein levels of Akt, ERK, GSK3B, mTOR, S6K and FKHR were immunohistochemically examined using antibodies for phosphorylated proteins designated by pAkt, etc. Also, thyroid transcription factor-1 (TTF-1) was examined for cell lineage analysis. The primary antibodies and citrate buffer used in this study are listed in Suppl. Table 1 and details of our immunohistochemical technique are also available on this. Antigen–antibody complexes were detected by labeling with the Envision+/HRP system (DAKO, Carpinteria, CA, USA), using 3,3′-diaminobenzidine tetrachloride as the chromogen and hematoxylin as counterstain. As well as using some normal cells as internal controls, mouse xenografts of the three cancer cell lines (PC-3, a prostate cancer line, showing high pAkt and low pERK expression, U251, a brain tumor line, showing moderate pAkt and low pERK expression and HTB26, a breast cancer line, showing low pAkt and high pERK expression) were included as external controls (Fig. 1), because we sought better quantification of immunoreactivity of each antibody by using well-known cell lines with well-documented reactivity. Immunoreactivity of each case was evaluated for all the tumor cells (or other cells of interest) appearing in all the three portions, applying the staining results for these xenografts. Essentially, for pAkt and pFKHR cytoplasmic staining (Fig. 1 and Suppl. Fig. 1), and for pS6K and pGSK3B whole cell staining were evaluated respectively, referring to the U251 levels. For pmTOR staining, comparison was with HTB26. All these were recorded as dichotomous parameters categorized as "negative" (weaker than or equal to xenograft staining) and "positive" (stronger than xenograft staining). For pERK immunoreactivity, the percentages of cells with positive staining were recorded and a score of 10% or less was categorized as "negative" and a score of more than 10% as "positive".

2.4. Mutation analysis of EGFR and KRAS

The mutation status of four exons of the *EGFR* gene and three codons of the *KRAS* gene was evaluated in the subset ($n = 93$) of the 193 cases. The primer sequences for exons 18 and 21 of *EGFR* were as follows (forward and reverse, respectively), exon 18 (5′-TCCAAATGAGCTGGCAAGTG-3′ and 5′-TCCCAAATACTCAGTGAACAAA-3′), exon 21 (5′-GATGCAGAGCTTCTTCCCAT-3′ and 5′-ATACAGCTAGTGGGAAG GCA-3′). For *KRAS*, codon 12 and codon 13 (5′-CCTTATGTGTGACATGTTCT-3′ and 5′-CTATTGTTGGATCATATTCG-3′), codon 61 (5′-TTCCTACAGGAAGCAAGTA-3′ and 5′-GGCAAATACACAAAGAAAGC C-3′). All PCR assays were carried out in a 20 μL volume that contained 0.2 μL of Taq DNA polymerase (NEB Phusion TM High Fidelity DNA polymerase sets, Finnzymes Oy, Finland). DNA was amplified for 35 cycles at 98 °C for 10 s, 60 °C for 30 s, and 72 °C for 30 s, followed by a 7 min extension at 72 °C. All PCR products were incubated with exonuclease I and shrimp alkaline phosphatase (USB corporation, Exo SAP-IT, OH, USA) according to the manufacturer's instructions and then sequenced directly by a cycle sequencing method (Beckman Coulter Inc, DTLS-Quick Start Kit, CA, USA). All sequence variants were confirmed by sequencing the products of independent PCR amplifications in both directions. To detect deletion in exon 19 and insertion in exon 20 of *EGFR*, common fragment analysis was used. Sample DNA was amplified with a Cy5-labeled primer set as follows: exon 19 (5′ Cy5-GTCTTCCTTCTCTCTCTGTCAT-3′ and 5′-TGTGGAGA GTGAGCAGGGTCT-3′), exon 20 (5′ Cy5-ACCATGCGAAGCCACACTGA-3′ and 5′-TCCTTATCTCCCCTCCCCGTAT-3′) and any deletion or insertion mutation was detected as a new peak of amplified products in the electrophoregram.

2.5. Statistical analysis

Statistical analyses were accomplished with STATA software, version 9 (Stata Corp. LP, College Station, TX, USA) and statistical programming language of R [13]. We studied the relationships between the survival and other clinicopathological factors and phospho-protein expression by univariate analyses of log-rank test. Then multivariate analyses using Cox regression model together with an AIC (Akaike Information Criteria) stepwise selection were applied to those factors to evaluate their relative risks. Then, correlation coefficients between each clinicopathological or



Fig. 1. Immunohistochemical staining of xenografts with specific antibody against pAkt (the upper row) and pERK1/2 (the lower row). (a) HTB-26; xenograft of breast cancer cell negative for pAkt and positive for pERK1/2; (b) U251; xenograft of glioma cell moderately positive for both pAkt and pERK1/2; (c) PC-3; xenograft of prostate cancer cell positive for pAkt and negative for pERK1/2. Almost all the cells with mitotic figure were scattered and were positive for pERK1/2. Immunohistochemical staining of resected lung specimen with specific antibody against pAkt (the upper row) and pERK1/2 (the lower row). Normal lung tissues (left side) and lung adenocarcinoma of noninvasive, acinar predominant and solid predominant histology (the right side). See that pAkt is almost homogeneously stained compared to that of pERK1/2.

immunohistochemical parameter were calculated and p-values for the statistical significance were given by a two-tails test checking a null hypothesis about zero Pearson's correlation coefficient between two variables.

Two-sided p-value below 0.05 was designated statistically significant.

3. Results

Patient characteristics of the 193 cases and differences in survival according to each clinicopathological factor or protein expression were shown in Table 1.

3.1. Patients and pathological review

The gender distribution was equal, the median age was 63 years and the median follow-up period was 2066 days (5.66 years) (ranged 133–3292 days). Pathological review revealed that more than 80% of the cases were classified as the adenocarcinoma with mixed subtype according to the current WHO classification. Therefore results based on the predominance classification together with invasive/noninvasive dichotomy were presented here. 22.8% ($n = 44$) of the cases were classified as pre- and minimally invasive adenocarcinomas. The rest (77.2%; $n = 149$) were invasive adenocarcinoma in which papillary (including micropapillary), acinar, solid patterns or patterns of other variants are predominantly recognized. The rates were 61.1% ($n = 118$), 9.9% ($n = 19$) and 6.2% ($n = 12$), respectively.

3.2. Immunohistochemical study and the EGFR/KRAS mutation status

We observed rather homogeneous and tumor-specific staining patterns for pAkt although the intensity was low, 37.8% (73/193) of surgically excised lung adenocarcinomas being positive. The positive rates for pGSK3B, pmTOR, pS6K, pFKHR and TTF-1 were 30.6% ($n = 59$), 34.7% ($n = 68$), 52.3% ($n = 101$), 40.4% ($n = 78$) and 79.8% ($n = 154$), respectively. The pERK staining pattern was characteristically heterogeneous. The rate of positive tumor cells ranging from 5% to 100% and the staining was not tumor-cell specific but rather

Table 1
Characteristics of the patients ($n = 193$) and differences* in survival rate according to each factor.

	N	5-Year survival (%)	95% CI	p-Value*
Patient and tumor characteristics				
Gender				
Male	96	71.6	0.61–0.80	0.027
Female	97	85.3	0.76–0.91	
Age				
<60	74	81.4	0.70–0.89	0.274
60 or older	119	76.5	0.67–0.83	
Smoking habit				
Never	89	83.2	0.73–0.90	0.151
Ever	104	74.3	0.64–0.82	
Stage				
I	120	94.8	0.89–0.98	<0.001
II–IV	73	48.7	0.36–0.61	
Adenocarcinoma classification				
Pre + minimally invasive**	44	96.5	0.83–0.99	<0.001
Invasive**	149	72.9	0.65–0.80	
Expression status (IHC study)				
pAkt				
−	120	85.3	0.77–0.91	0.007
+	73	68.2	0.56–0.79	
pERK				
−	124	73.8	0.65–0.81	0.058
+	69	86.4	0.76–0.93	
pGSK3B				
−	134	76.7	0.68–0.83	0.289
+	59	82.0	0.69–0.90	
pmTOR				
−	125	75.7	0.77–0.83	0.214
+	68	83.1	0.71–0.90	
pS6K				
−	92	74.1	0.63–0.82	0.260
+	101	82.3	0.73–0.89	
pFKHR				
−	115	85.6	0.77–0.91	0.006
+	78	68.1	0.56–0.77	
TTF-1				
−	39	49.4	0.32–0.65	<0.001
+	154	85.5	0.79–0.90	
Mutation status ($n = 93$)				
EGFR mutation				
−	39	69.2	0.52–0.81	0.175
+	54	84.8	0.72–0.92	
KRAS mutation				
−	86	78.7	0.68–0.86	0.774
+	7	71.4	0.26–0.92	

* Log-rank test (p-value); CI: confidence interval; N: lymph node metastasis.
** Pre + minimally invasive: adenocarcinoma in situ + lepidic pattern predominant adenocarcinoma with minimal invasion (<10% or ≤5 mm invasion); Invasive: adenocarcinoma of papillary (including micropapillary), acinar or solid pattern predominant and other variants; IHC: immunohistochemistry; TTF-1: thyroid transcription factor-1; pAkt: phosphorylated Akt; pERK: phosphorylated extracellular signal-regulated kinase; pGSK3β: phosphorylated glycogen synthase kinase 3β; pmTOR: phosphorylated mammalian target of rapamycin; pS6K: phosphorylated ribosomal protein S6 kinase; pFKHR: phosphorylated forkhead transcription factors.

ubiquitous. The contrast between positive and negative cells was excellent. With the 10% cutoff, 35.8% (69/193) of the tumors were positive for pERK (Fig. 1).

The results of mutation analysis of exons 18–21 of *EGFR* and codons 12, 13 and 61 of *KRAS* are detailed in Suppl. Table 2. *EGFR* mutations were detected in 54 cases (58.1%), among which 90% were in exons 19 and 21. Mutations of *KRAS* were seen in seven cases (7/93, 7.5%), all of which were at codon 12. The *EGFR* and *KRAS* mutations were mutually exclusive except in one case. Of note, both pAkt and pERK were strongly stained in this case with double mutation of *EGFR* and *KRAS*. Types of *EGFR* mutation did not appear to affect the pattern of pathway activation. All but one of the cases with *KRAS* mutation were strongly positive for pERK ($p = 0.009$, Table 4), whereas the *EGFR* mutation did not correlate to pERK ($p = 0.294$) nor pAkt ($p = 0.409$) expression.

3.3. Patient survival

By univariate analyses using log-rank test, gender ($p = 0.027$), stage ($p < 0.001$), adenocarcinoma classification (invasive or not) ($p < 0.001$), expression of TTF-1 ($p < 0.001$) and cytoplasmic staining of pAkt ($p = 0.007$) and pFKHR ($p = 0.006$) were significantly related

Table 2
Multivariate analysis for factors predicting poor prognostic outcome ($n = 193$).

Variable	Relative risk	95% CI	p-Value
Cox regression analysis			
Patient and tumor characteristics			
Female	0.48911	0.25–0.93	0.030
Age (60 or older)	1.43993	0.75–2.78	0.268
Ex or current smoker	1.58799	0.84–3.00	0.147
Stages II–IV	10.96302	5.02–23.92	<0.001
Adenocarcinoma classification (invasive*)	1.81110	1.05–2.73	0.030
Expression status (IHC study)			
TTF-1+	0.24379	0.13–0.45	<0.001
pAkt+	2.28909	1.22–4.29	0.009
pERK+	0.50813	0.25–1.04	0.051
pGSK3B+	0.68778	0.34–1.40	0.289
pmTOR+	0.64731	0.32–1.29	0.204
pS6K+	0.70277	0.38–1.30	0.260
pFKHR+	2.34981	1.26–4.38	0.007
Mutation status ($n = 93$)			
EGFR mutation	0.56279	0.24–1.31	0.180
KRAS mutation	1.23578	0.29–5.29	0.780
Cox regression analysis with step wise selection			
Female	0.54	0.27–1.06	0.074
Stages II–IV	10.542	4.61–24.1	<0.001
pAkt+	2.268	1.17–4.38	0.015
pFKHR+	1.812	0.95–3.48	0.073
TTF-1+	0.282	0.15–0.54	<0.001

* CI: confidence interval; invasive: adenocarcinoma with a frankly invasive region; TTF-1: thyroid transcription factor-1; pAkt: phosphorylated Akt; pERK: phosphorylated extracellular signal-regulated kinase; pGSK3β: phosphorylated glycogen synthase kinase 3β; pmTOR: phosphorylated mammalian target of rapamycin; pS6K: phosphorylated ribosomal protein S6 kinase; pFKHR: phosphorylated forkhead transcription factors.

to survival (Table 1). Multivariate analysis using the Cox's proportional hazard model revealed that stage ($p < 0.001$), expression of TTF-1 ($p < 0.001$) and pAkt ($p = 0.015$) are statistically significant factors for prognosis independent of any other conditions (Table 2).

3.4. Clinicopathological backgrounds of adenocarcinomas with Akt activation or TTF-1 expression

Since pAkt and TTF-1 expression was revealed to be independent prognostic factors, relationships between their positive status and other factors including clinicopathological characteristics and expression of other phosphorylated proteins are summarized in Table 3. pAkt expression was significantly associated with advanced stage (stage II-IV, $p = 0.021$) and lymph node metastasis ($p = 0.002$) but not with expression of any other signal proteins or TTF-1. TTF-1 expression, on the contrary, was significantly associated with never-smoker status ($p = 0.013$) and pre- or minimally invasive nature ($p < 0.001$) as well as with expression of pERK ($p = 0.039$) and pmTOR ($p = 0.014$). Also, TTF-1 expression was related to *EGFR* mutation ($p = 0.017$). Regarding invasiveness of tumor, the pAkt activation frequency tended to be lower in the pre- and minimally invasive adenocarcinomas (18.2%; 8/44) as compared with invasive types (43.6%; 65/149) and this tendency was highly and statistically significant ($p = 0.004$). In contrast, TTF-1 staining was more frequently seen among the pre- and minimally invasive adenocarcinomas ($p < 0.001$).

Correlation coefficients between each factor were shown in Table 4. The general tendency was largely in concert with results of survival analysis (Tables 1 and 2) and expression of Akt and TTF-1. Interestingly, activation of signal proteins of ERK had similar and statistically (or marginally) significant correlation to nonsmoking ($p = 0.035$), stage I ($p = 0.029$) and noninvasive status ($p = 0.001$). GSK3B expression was related significantly to activation of ERK ($p = 0.001$), mTOR ($p < 0.001$) and S6K ($p = 0.018$). *EGFR* mutations were significantly associated with female gender ($p = 0.031$), non-smokers ($p = 0.016$), TTF-1 expression ($p = 0.008$) and pS6K expression ($p = 0.008$).

4. Discussion

By IHC applied to primary adenocarcinoma tissues and mouse xenografts of cell lines used as controls, we succeeded in demonstrating Akt activation to be an independent marker of poor prognosis. In addition, TTF-1, which is known to be a marker of type II cell differentiation, was also proved to be a significant favorable prognostic marker in correlation with activation of ERK and mTOR or *EGFR* mutation regardless of tumor stages. The expression of TTF-1 is important in outcome estimation of lung carcinoma at any tumor stage whereas Akt activation is abnormally affected according to the aggressiveness of the tumors regardless of their cell origin. While *EGFR* mutations had no correlation to activation of Akt or ERK pathways, six of seven cases with *KRAS* mutation were remarkably stained for pERK throughout the tumors. Finally, FKHR expression was established to be a marker for poor prognosis.

This study demonstrated that activated Akt was associated independently and significantly with poor prognosis ($p = 0.015$), which was in agreement with previous studies [14–19]. In fact, pAkt expression correlated with factors such as stages II-IV, positive lymph node metastasis and the invasive histology (Table 3), suggesting that Akt activation is an acquired characteristic according to tumor aggressiveness. To cast light on actual regulators and substrates of Akt that might mediate regulatory mechanisms in primary lung adenocarcinoma, we compared the activation status of Akt with upper and downstream components of the signal transduction. However our results somewhat differed from those obtained earlier with cell lines. For example, *EGFR* mutations in NSCLC cell lines were reported to selectively activate the Akt pathway [3], but in our primary tumors, this correlation between Akt and constitutively activated RTK was not significant ($p = 0.409$). Moreover, in our study, expression of pAkt did not correlate with activation of any of the downstream signal proteins such as GSK3B, mTOR, S6K and FKHR in the burgeoning list of Akt substrates implicated in oncogenesis [20,21]. Linkage of Akt with those activated downstream signal proteins has been confirmed in vitro, but the results in clinical samples have been inconsistent [18,22–24]. Certainly, Akt activation is an important factor for development and proliferation of cancer cells and perhaps a marker for targeted therapies, the exploration of this area especially in real tumors has definitely been inadequate and further study is needed.

Our multivariate analysis revealed that TTF-1 expression was also a statistically significant and independent prognostic factor ($p < 0.001$). TTF-1 is a regulator of normal lung development or maintenance of type II pneumocytes [25] and was expressed in 79.8% (154/193) of the cases. Recently, a model of lineage specific dependency on TTF-1 in a subset of adenocarcinoma, that is, the terminal respiratory unit (TRU) type adenocarcinoma, has been proposed [26]. In our study, TTF-1 staining was correlated with never-smoker ($p = 0.013$) and *EGFR* mutation status ($p = 0.039$) independently of tumor stage, which is consistent with the concept of lineage specific tumorigenesis in this subset of lung adenocarcinoma. These insights suggest the importance of the cell lineage that tumors were derived from in outcome estimation of lung carcinoma.

ERK was activated in 35.8% (69/193) of the cases in our study and was associated with pathologically early stages, the pre or minimally invasiveness and TTF-1 expression ($p = 0.039$). Normal tissues, such as type II pneumocytes or interstitial fibroblasts, were also positive with varying intensity (Fig. 1). Generally, ERK activation is known not only as the result of oncogenic dysregulation

Table 3
Backgrounds of patients with expression of a significant prognostic factors; pAkt and TTF-1 ($n = 193$).

	No. of cases with expression of pAkt and TTF-1 (%)				
	Total 193	pAkt 73 (37.8)	p-Value*	TTF-1 154 (79.8)	p-Value*
Patient and tumor characteristics					
Gender					
Male	96	33 (35.1)	0.371	73 (76.0)	0.214
Female	97	40 (42.1)		81 (83.5)	
Age					
<60	74	30 (40.5)	0.760	62 (83.8)	0.357
60 or over	119	43 (37.4)		92 (77.3)	
Smoking habit					
Never	89	37 (42.0)	0.374	78 (87.6)	0.013
Ever	104	36 (35.6)		76 (73.1)	
Stage					
I	120	37 (31.9)	0.021	99 (82.5)	0.269
II–IV	73	36 (49.3)		55 (75.3)	
N					
−	135	41 (31.3)	0.002	112 (83.0)	0.118
+	57	32 (56.1)		42 (73.7)	
Adenocarcinoma classification**					
Pre + minimally invasive	44	8 (18.2)	0.004***	44 (100.0)	<0.001
Invasive	149	65 (43.6)		110 (73.8)	
Pap-pred	118	52 (44.1)		91 (77.1)	
Acinar-pred	19	9 (47.4)		14 (73.7)	
Solid-pred and other variants	12	4 (33.3)		5 (41.7)	
Other IHC results					
pAkt					
−	120			94 (78.3)	0.851
+	73			58 (79.5)	
pERK					
−	124	51 (41.8)	0.275	93 (75.0)	0.039
+	69	22 (32.8)		61 (88.4)	
pGSK3B					
−	134	48 (36.6)	0.421	103 (76.9)	0.331
+	59	25 (43.1)		50 (84.7)	
pmTOR					
−	125	49 (39.2)	0.754	93 (74.4)	0.014
+	68	24 (35.3)		61 (89.7)	
pS6K					
−	92	39 (42.4)	0.370	73 (79.3)	1.000
+	101	34 (33.7)		81 (80.2)	
pFKHR					
−	115	39 (33.9)	0.879	87 (75.7)	0.101
+	78	34 (43.6)		67 (85.9)	
TTF-1					
−	39	15 (38.4)	0.851		
+	154	58 (37.7)			
Mutation status ($n = 93$)					
EGFR mutation					
−	39	16 (41.0)	0.409	26 (66.7)	0.017
+	54	27 (50.0)		48 (88.9)	
KRAS mutation					
−	86	41 (47.7)	0.445	70 (81.4)	0.148
+	7	2 (28.6)		4 (57.1)	

* Results of Fisher's exact test; pAkt: phosphorylated Akt; TTF-1: thyroid transcription factor-1; N; lymph node metastasis.
** Adenocarcinoma classification; see text for details; -pred: predominant; Pap: papillary pattern including micropapillary pattern; Acinar: acinar pattern; Solid: solid with mucin formation pattern.
*** Comparison between "Preinvasive + minimally invasive" vs other "invasive" carcinoma; IHC: immunohistochemistry; pERK: phosphorylated extracellular signal-regulated kinase; pGSK3B: phosphorylated glycogen synthase kinase 3B; pmTOR: phosphorylated mammalian target of rapamycin; pS6K: phosphorylated ribosomal protein S6 kinase; pFKHR: phosphorylated forkhead transcription factors.

Table 4
Correlation analysis of clinicopathological data, expression of phosphoryated proteins and mutation status.

N=193	Gender [Female]	Age [60≦]	Smoking habit [Ever]	Stage [II-IV]	Adenocarcinoma Classification [Invasive]	TTF-1 [+]	pAkt [+]	pERK [+]	pGSK3B [+]	pmTOR [+]	pS6K [+]	pFKHR [+]	*EGFR* mutation
Age [60≦]	-0.049	1											
Smoking habit [Ever]	-0.630 (<0.001)	0.011	1										
Stage [II-IV]	-0.063	-0.028	0.079	1									
Adenocarcinoma Classification [Invasive]	-0.021	0.058	-0.191	0.252 (<0.001)	1								
TTF-1 [+]	0.110	-0.058	-0.191 (0.009)	-0.087	-0.153 (0.039)	1							
pAkt [+]	0.083	-0.048	-0.069	0.185 (0.012)	0.107	-0.041	1						
pERK [+]	0.107	0.138	-0.156 (0.035)	-0.161 (0.029)	-0.235 (0.001)	0.178 (0.016)	-0.006	1					
pGSK3B [+]	0.098	-0.014	-0.119	-0.083	0.008	0.073	0.064	0.250 (<0.001)	1				
pmTOR [+]	0.164 (0.026)	-0.107	-0.213 (0.004)	-0.011	-0.160 (0.003)	0.203 (0.006)	-0.036	0.246 (<0.001)	0.234 (0.001)	1			
pS6K [+]	0.279 (<0.001)	0.063	-0.257 (<0.001)	-0.086	-0.134 (0.072)	0.054	-0.049	0.175 (0.018)	0.241 (0.001)	0.233 (0.001)	1		
pFKHR [+]	-0.029	-0.048	0.087	0.140	0.261 (<0.001)	-0.099	0.020	-0.138	0.040	-0.036	-0.096	1	
N=93													
EGFR mutation	0.224 (0.031)	0.040	-0.249 (0.016)	0 (1.000)	0.063	0.272 (0.008)	0.089	0.112	0.111	-0.005	0.274 (0.008)	-0.181	1
KRAS mutation	0.032	-0.024	0.125	-0.115	-0.012	-0.159	-0.101	0.268 (0.009)	0.051	0.095	0.044	0.072	-0.253 (0.014)

Correlation coefficients were calculated assuming the conditions described in the parenthesis [ ] to be observed. For abbreviations, see text. Coefficients values highlighted by underline imply statistical significance. Numbers in ( ) are *p*-values. For details of invasiveness, see text. Darkly shadowed cells imply significantly positive correlation and weakly shadowed cells imply significantly (or marginally) negative correlation. TTF-1: thyroid transcription factor-1; pAkt: phosphorylated Akt; pERK: phosphorylated extracellular signal-regulated kinase; pGSK3B: phosphorylated glycogen synthase kinase 3B; pmTOR: phosphorylated mammalian target of rapamycin; pS6K: phosphorylated ribosomal protein S6 kinase; pFKHR: phosphorylated forkhead transcription factors.

but also as an essential component of epithelial cell development or adaptation to changing circumstances [27–29]. Moreover, ERK regulation depends on very complex mechanisms, involving several intracellular parameters [30], timing or balance of the signals [31–34] and other unknown factors [35]. Considering these arguments, we may conjecture that ERK activation in lung adenocarcinoma mostly reflects the intracellular signal transduction of normal cells, which is still preserved within early-staged adenocarcinoma especially with TTF-1 expression, and that the ERK pathway is gradually switched off as the tumor cells progress to a more malignant phenotype. Also, these results shown here is in line with the recent studies of American cases [36], where the ERK pathway was more activated in earlier stages and the Akt pathway in advanced stages. In further studies, considering significant heterogeneity of ERK activation, we may use more detailed judgment criteria for immunoreactivity and whole sections of tumor, rather than tissue microarrays.

Six of seven cases with *KRAS* mutation were remarkably stained for pERK throughout the tumors, consistent with previous reports [37,38]. It is notable that the clinical impact of such *KRAS* mutation-induced ERK activation is enormous since it has already been shown in mice models that tumors with ERK activation due to *KRAS* or *BRAF* mutations can be successfully treated by an inhibitor of MEK, a signal protein upstream of ERK [39]. Our results imply so far the presence of at least two causes for ERK activation in lung adenocarcinoma, one is the vestige of normal intracellular signal and the other is the impact of *KRAS* mutation.

Two other supplementary implications were obtained from this study. Among downstream proteins of the Akt pathway, only S6K was significantly expressed in cases with the *EGFR* mutation ($p = 0.008$) and may potentially be an alternative marker for *EGFR* mutation. S6K is known to regulate ribosomal biogenesis and to play an important role in progression of G1 phase of the cell cycle [41,42]. This correlation between *EGFR* and S6K suggests again a cross talk between the Akt and ERK pathways and similar result was previously described by Conde et al. [40]. Our results also indicated cytoplasmic localization without intranuclear accumulation of pFKHR protein to be an adverse prognostic factor. FKHR is a member of a transcription factor family and represents a mammalian counterpart of DAF16, first identified at chromosomal breakpoints in human tumors [20]. Subcellular localization of FKHR is known to play an important role by regulating cell cycle and apoptosis in normal cell, which is consistent with our result. Further accumulation of cases will be needed to confirm those possibilities.

As a reference for IHC evaluation we here used mouse xenografts selected from a cell line panel repeatedly used in drug research [12,43]. This resulted in more accurate and reproducible evaluation of protein expression, implying the usefulness of tumor xenografts for clinical researches.

Conflict of interest statement

Kengo Takeuchi is a consultant for DAKO.

Acknowledgements

We thank Dr. Michiyo Okui for discussion, Ms. Kazuko Yokokawa, Ms. Miyuki Kogure, Mr. Motoyoshi Iwakoshi, Ms. Tomoyo Kakita and Ms. Yuki Togashi for their technical assistance, and Ms. Yuki Takano and Ms. Hiroko Nagano for secretarial help.

Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, from the Japan Society for the Promotion of Science, grants from the Ministry of Health, Labour and Welfare, the Smoking Research Foundation, the National Institute of Biomedical Innovation, and the Vehicle Racing Commemorative Foundation.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.lungcan.2010.01.001.

References

[1] Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
[2] Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237–46 [corrected].
[3] Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163–7.
[4] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.
[5] Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153–83.
[6] Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180–6.
[7] Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983–5.
[8] Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:599–602.
[9] Virtanen C, Ishikawa Y, Honjoh D, Kimura M, Shimane M, Miyoshi T, et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci USA 2002;99:12357–62.
[10] Sobin LH, Wittekind C, editors. International Union Against Cancer: TNM classification of malignant tumors. 5th ed. New York, NY: Wiley-Liss; 1997. p. 91–7.
[11] Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of lung, pleura, thymus and heart. Lyon, France: IARC; 2004.
[12] Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 1999;59:4042–9.
[13] Team RDC. R: a language and environment for statistical computing; 2007. Available from http://www.R-project.org.
[14] Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006;51:181–91.
[15] Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178–86.
[16] Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, et al. Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 2006;13:933–9.
[17] Kobayashi I, Semba S, Matsuda Y, Kuroda Y, Yokozaki H. Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma. Pathobiology 2006;73:8–17.
[18] Lin HJ, Hsieh FC, Song H, Lin J. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer 2005;93:1372–81.
[19] Kim TJ, Lee JW, Song SY, Choi JJ, Choi CH, Kim BG, et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 2006;94:1678–82.
[20] Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857–68.
[21] Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004;167:399–403.
[22] Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053–9.
[23] Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006;19:238–45.
[24] Dobashi Y, Suzuki S, Matsubara H, Kimura M, Endo S, Ooi A. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 2009;115:107–18.
[25] Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005;29:633–9.
[26] Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S, et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007;67:6007–11.
[27] Iwagaki A, Choe N, Li Y, Hemenway DR, Kagan E. Asbestos inhalation induces tyrosine nitration associated with extracellular signal-regulated kinase 1/2 activation in the rat lung. Am J Respir Cell Mol Biol 2003;28:51–60.
[28] Yoshida K, Kuwano K, Hagimoto N, Watanabe K, Matsuba T, Fujita M, et al. MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis. J Pathol 2002;198:388–96.

[29] Farivar AS, Woolley SM, Fraga CH, Byrne K, Mulligan MS. Proinflammatory response of alveolar type II pneumocytes to in vitro hypoxia and reoxygenation. Am J Transpl 2004;4:346–51.
[30] Murphy LO, Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci 2006;31:268–75.
[31] Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179–85.
[32] Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999–9006.
[33] Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: it ain't over 'til it's over. Trends Cell Biol 2000;10:147–54.
[34] Sun P, Watanabe H, Takano K, Yokoyama T, Fujisawa J, Endo T. Sustained activation of M-Ras induced by nerve growth factor is essential for neuronal differentiation of PC12 cells. Genes Cells 2006;11:1097–113.
[35] Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189–98.
[36] Sarkaria IS, Zakowski MF, Pham D, Hezel M, Ebright MI, Chuai S, et al. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. Ann Thorac Surg 2008;85:216–23.
[37] Devereux TR, Holliday W, Anna C, Ress N, Roycroft J, Sills RC. Map kinase activation correlates with K-ras mutation and loss of heterozygosity on chromosome 6 in alveolar bronchiolar carcinomas from B6C3F1 mice exposed to vanadium pentoxide for 2 years. Carcinogenesis 2002;23:1737–43.
[38] Schmitz KJ, Wohlschlaeger J, Alakus H, Bohr J, Stauder MA, Worm K, et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch 2006.
[39] Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007;67:4933–9.
[40] Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A, et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 2006;12:710–7.
[41] Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, et al. Phosphorylation and activation of p70s6k by PDK1. Science 1998;279:707–10.
[42] Pearson RB, Thomas G. Regulation of p70s6k/p85s6k and its role in the cell cycle. Prog Cell Cycle Res 1995;1:21–32.
[43] Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006;98:545–56.

Is the Epidermal Growth Factor Receptor Status in Lung Cancers Reflected in Clinicopathologic Features?

Kentaro Inamura, MD, PhD; Hironori Ninomiya, MD; Yuichi Ishikawa, MD, PhD; Osamu Matsubara, MD, PhD

• *Context.*—Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are molecular-targeted drugs that are innovatively effective for non–small cell lung carcinomas with *EGFR* mutations. Epidermal growth factor receptor is a transmembrane receptor forming dimers on ligand binding. These then stimulate signals by activating receptor autophosphorylation through tyrosine kinase activity. Autophosphorylation triggers intracellular pathways facilitating malignant conversion. The most clinically advanced EGFR inhibition strategies include small-molecule inhibition of the intracellular tyrosine kinase domain (gefitinib and erlotinib) and monoclonal antibody–mediated blockade of the extracellular ligand-binding domain (cetuximab). Lung cancers with *EGFR* mutations are prevalent among patients who are female, of Asian ethnicity, and nonsmokers; thus, they can obtain benefit from EGFR tyrosine kinase inhibitors.

***Objective.*—To survey histopathologic findings and examine correlations with *EGFR* mutations. We mainly focused on component cell types (hobnail, columnar, and polygonal) and presence or absence of bronchioloalveolar carcinoma elements and a micropapillary pattern. Although *EGFR* mutations can be detected by various methods, including polymerase chain reaction–Invader assay or direct sequencing, these are inconvenient.**

***Data Sources.*—Review of the published literature.**

***Conclusion.*—Detailed pathologic examination showed significant genotype-phenotype correlations between *EGFR* mutations and presence of a bronchioloalveolar carcinoma component, a micropapillary pattern, and the hobnail cell type. We conclude that these characteristic histologic features are good predictors of *EGFR* mutations, and patients with these features might be good candidates for and could benefit from therapy with EGFR tyrosine kinase inhibitors.**

(*Arch Pathol Lab Med.* 2010;134:66–72)

The epidermal growth factor receptor (EGFR), a receptor of ligands including epidermal growth factor (EGF), is a 170-kDa glycoprotein tyrosine kinase protein that straddles the cell membrane.

Expression of EGFR is prevalent in variant normal cells including cells of epidermal, mesenchymal, and neurogenic origins. When EGF binds to EGFR, signaling pathways are activated that can lead to cell proliferation and differentiation. Epidermal growth factor receptor plays an important role in cell differentiation, development, proliferation, and maintenance. With *EGFR* gene overexpression due to mutation or structural alteration, carcinogenesis, invasion, and metastasis are facilitated.

In recent years there has been substantial interest in developing novel therapeutic agents that specifically target growth factor pathways that are dysregulated in cancer cells. Non–small cell lung cancer (NSCLC) is the most frequent cause of cancer death in the world and targeting EGFR has played a central role in advancing NSCLC research to improve patient outcome during the last several years. With the move to personalized cancer therapy, we need to understand oncologic biology at the molecular and histopathologic levels in individual lesions. In this review article, we focus on clinicopathologic features related to EGFR change and consider their indications for clinical application.

GENE MUTATIONS IN NON–SMALL CELL LUNG ADENOCARCINOMAS

Lung cancer is the leading cause of cancer death in men and women worldwide and identification of activating mutations of *EGFR* is one of the most intriguing recent discoveries in the field of lung cancer research.[1,2] Epidermal growth factor receptor mutations are present in a particular subtype of lung adenocarcinomas, and cancers with this mutation have been shown to be highly sensitive to chemical inhibitors of the kinase activity of EGFR. This subtype is prevalent among patients who are female, of Japanese and other Asian ethnicity, and nonsmokers.[2–4] K-ras is a downstream mediator of EGFR-induced cell signaling, and K-ras mutations confer constitutive activation of the signaling pathways without EGFR activation. Growing evidence indicates that K-ras mutations are also important in the development of lung carcinomas.[5] Very recently, we found a novel transforming fusion gene resulting from linkage between the echinoderm microtubule-associated protein like 4 (*EML4*) and anaplastic lymphoma

Accepted for publication February 20, 2009.

From the Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan (Drs Inamura and Ishikawa); and the Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama, Japan (Drs Ninomiya and Matsubara).

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Osamu Matsubara, MD, PhD, Department of Basic Pathology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan (e-mail: matubara@ndmc.ac.jp).



Figure 1. *The epidermal growth factor receptor (EGFR) family proteins and their ligands. TGF, transforming growth factor; HB-EGF, heparin-binding epidermal growth factor–like growth factor; HER, human epidermal growth factor receptor.*

kinase (*ALK*) genes in NSCLCs.[6] This translocation promotes strong tyrosine kinase activity, which is a prominent feature of ALK, leading to intensive oncogenesis in NSCLCs. Cancers featuring *EML4-ALK* fusion thus constitute a subtype of NSCLCs that might be highly sensitive to ALK inhibitors. Interestingly, *EGFR* mutation, K-ras mutation, and *EML4-ALK* translocation are mutually exclusive.[7,8] Furthermore, lung cancers with each of these alterations appear to have their own particular clinicopathologic characteristics.

DISCOVERY OF EGFR

In 1975, the existence of the EGF-specific receptor was first reported on the cell membrane of the fibroblast.[9] Thereafter, from work with the A431 human cancer cell line, EGFR was initially defined as a 170-kDa protein.[10] In 1984, the sequence of v-*erbB*, an oncogene of the avian erythroblastic leukemia virus, was reported to be extremely similar to that of EGFR.[11] Gene products of oncogene *erbB* and *EGFR* subsequently turned out to be identical proteins. Thereafter, it was found that human genes corresponding to v-*erbB* were not only *EGFR* but also human epidermal growth factor receptor 2 (*HER2*), these 2 now being referred to as *ERBB1* and *ERBB2*, respectively.

STRUCTURE AND FUNCTION OF EGFR

Growth factors belong to a family of polypeptides that have been shown to stimulate proliferation and/or differentiation in both normal and malignant cells. One of the first growth factors discovered was EGF. Later studies showed that this protein binds to the cell surface growth factor receptor EGFR, thereby either inducing cell proliferation or differentiation in mammalian cells.

The binding of a ligand to EGFR induces conformational changes within the receptor, which increase the catalytic activity of its intrinsic tyrosine kinase, resulting in the autophosphorylation that is necessary for biologic activity. Epidermal growth factor receptor is a 170-kDa transmembrane glycoprotein that binds to specific ligands. The erbB family cell-signaling process uses EGF-like ligands that include cell-signaling transforming growth factor α (TGF-α), amphiregulin, heparin-binding EGF, epiregulin, heregulin, neuregulin, and betacellulin. Epidermal growth factor receptor is known to bind with particularly high affinity to EGF, amphiregulin, and TGF-α.

As noted above, EGFR is a member of the erbB family of receptor tyrosine kinase proteins, now known to also include HER2/*neu* (erbB2), HER3 (erbB3), and HER4 (erbB4). These receptors are all composed of an extracellular ligand-binding domain, a transmembrane lipophilic domain, and an intracellular tyrosine kinase domain and, with the exception of HER2, all bind to receptor-specific ligands (Figure 1). Phosphorylation of the tyrosine kinase domain followed by homodimerization or heterodimerization between receptors of the same family leads to protein activation on the cell surface. In cancer cells, this is believed to promote signaling cascades, cell growth, differentiation, cell survival, cell cycle progression, and angiogenesis.

GENETIC STRUCTURE OF EGFR

The approximately 200-kb human *EGFR* gene, comprising 28 exons and 27 introns, exists on the short arm of chromosome 7 (7p12). Exons 1 to 16 encode the extracellular domain, while exon 17 codes for the transmembrane domain, and exons 18 to 28 are responsible for the intracellular domains. The tyrosine kinase domain is encoded by exons 18 to 24, while the C-terminal domain is encoded by exons 25 to 28.

ACTIVATION OF EGFR DOWNSTREAM SIGNALING

Receptor tyrosine kinases, such as EGFR, transmit extracellular signals of growth factors into the intracytoplasmic region and transmit their stimulus to the nuclei by signal transduction. As a result, transcriptional upregulation follows, leading to protein synthesis and transformation of cell functions or cellular architecture.

As signaling pathways of EGFR, the Ras/Raf/MAPK (mitogen-activated protein kinase) pathway, the PI3K (phosphatidylinositol-3-kinase)/Akt pathway, and the Jak (Janus kinase)/ STAT (signal transducers and activator of transcription) pathway are all important. As a result of



Figure 2. *Schematic illustration of the epidermal growth factor receptor (EGFR) and downstream signaling pathways. Binding of a receptor-specific ligand leads to phosphorylation of EGFR and signaling through the mitogen-activated protein kinase (MAPK) pathway (green), signal transducers and activator of transcription (STAT) pathway (blue), and phosphatidylinositol-3-kinase (PI3K)/Akt pathway (orange). These pathways promote cell proliferation, angiogenesis, migration, adhesion, and/or invasion, while inhibiting apoptosis. SOS, son of sevenless; Grb-2, growth factor receptor–bound protein 2; Ras and Raf are well-known oncoproteins; MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated kinase.*

Table 1. Epidermal Growth Factor Receptor (EGFR) Expression in Various Tumor Types

Tumor Type	Tumors Expressing EGFR, %
Head and neck	80–100
Renal	50–90
Lung	40–80
Breast	14–91
Colon	25–77
Ovarian	35–70
Prostate	39–47
Glioma	40–63
Pancreas	30–50
Bladder	31–48

the signal transduction, cell differentiation or cell proliferation are promoted. The Ras/Raf/MAPK pathway mainly promotes cell proliferation and survival, while the PI3K/Akt pathway is mainly associated with cell growth, inhibition of apoptosis, invasion, or migration (Figure 2).

EGFR OVEREXPRESSION

In a wide range of solid cancers, EGFR overexpression has been detected to varying degrees (Table).[12] Reported values are 30% to 38% for gastric adenocarcinomas,[13,14] 30% to 62% for pancreatic cancers,[15,16] and 100% for undifferentiated thyroid carcinomas.[17] Although the prognostic significance of EGFR expression remains unclear, as reports on these issues are contradictory, a retrospective review of EGFR studies determined that EGFR expression levels are highly predictive of clinical outcome for patients with ovarian, cervical, bladder, esophageal, and head and neck cancers. They are of moderate prognostic value for gastric, colorectal, breast, and endometrial cancers and of relatively low prognostic value for NSCLCs.[18]

EXTRACELLULAR MUTATION OF *EGFR*

In 1988, it was found that human glioblastoma multiforme cells carried amplified c-*erbB* genes that bore short deletion mutations within the ligand-binding domain of the EGFR. The products of these mutated c-*erbB* genes were about 30 kDa smaller than the normal 170-kDa EGFR, and cancer cell membrane fractions containing the 140-kDa abnormal EGFR showed a significant elevation of tyrosine kinase activity without any ligand.[19] This mutation type was referred to as EGFRvIII. There is no ligand binding site and the result is constant activation without any ligand binding.[20] EGFRvIII is associated with cell proliferation and malignancy in various neoplasms involving breast cancers, small cell lung cancers, gliomas, and prostatic cancers.[21]

MUTATIONS OF INTRACYTOPLASMIC DOMAIN OF *EGFR* GENE

In 2004, mutations of intracytoplasmic domain of *EGFR* gene were found in NSCLCs, and NSCLCs with such mutations were reduced in size by gefitinib, a chemical inhibitor of the kinase activity of EGFR.[1,2] In the gene coding for the receptor, mutations are divided into 4 major types: point mutations in exon 18, deletions in exon 19, insertions in exon 20, and point mutations in exon 21. Particularly, the 2 most frequent mutations are deletion around codons 746 to 750 of exon 19 and transversion of T to G in codon 858 of exon 21, with an amino acid change from leucine to arginine (L858R). These 2 mutations account for approximately 90% of intracytoplasmic mutations of EGFR (Figure 3).[22] They both cause conformational change in the ATP-binding domain, which results in constant activation of EGFR without ligand binding. However, affinity for gefitinib is upregulated, so that the cancer cells are susceptible to induction of apoptosis by this agent and to reduction in cancer size.[23] The 2 *EGFR* mutations have been found to be present in normal lung tissue around cancers,[24] and mice transgenic for the mutated *EGFR* gene develop lung cancers.[25] The results thus suggest that *EGFR* mutation is involved at an early stage of neoplasia in the lung.

EGFR MUTATIONS GENERATING GEFITINIB TOLERANCE

In addition to the EGFR mutations increasing sensitivity to gefitinib, as mentioned above, secondary mutations can occur so that cancers become tolerant. Substitution in codon 790, with a resulting amino acid shift from threonine to methionine (T790M),[1] or in codon 761, resulting in change from asparaginic acid to tyrosine (D761Y),[26] are reported to be gefitinib tolerance–inducing mutations. T790M has been detected in about half of the NSCLCs exhibiting acquired gefitinib tolerance.[26] Alteration of the gefitinib binding site in the EGFR cytoplasmic domain is presumably involved.



Figure 3. *Distribution of mutations in the epidermal growth factor receptor.*

DRUGS TARGETING EGFR

The most clinically advanced EGFR inhibition strategies include small-molecule inhibition of the intracellular tyrosine kinase domain and monoclonal antibody–mediated blockade of the extracellular ligand-binding domain. Gefitinib and erlotinib are oral anticancer drugs, inhibiting tyrosine kinase domain. Their cytoreductive effects are to some extent dependent on intracytoplasmic mutations of EGFR, as noted above, and they have been found to be useful in the treatment of NSCLCs. Cetuximab is a monoclonal antibody, binding to the ligand-binding site of EGFR and blocking its dimerization and activation. It is also effective for the wild-type EGFR, with applications in the treatment of colorectal as well as head and neck cancers.

EFFECT OF CANCER REDUCTION, COMBINATION USAGE OF CHEMOTHERAPY, AND LIFE PROLONGATION

From 2000 to 2001, 2 phase II studies of pretreated advanced NSCLCs (Iressa Dose Evaluation in Advanced Lung Cancer [IDEAL] 1 study[27] and IDEAL 2 study[28]) were performed. The positive response rate to gefitinib was 9% to 19% and the 1-year survival rate was 21% to 36%. Cancer reduction effects were most prevalent in Asian nonsmoking females with adenocarcinomas. Cancers with EGFR mutations demonstrated significant cytoreductive effects to treatment,[1,2] and this response is predominantly seen in persons with adenocarcinoma, who are nonsmokers, of female sex, and of Asian ethnicity.

From 2000 to 2001, as a first treatment for advanced NSCLCs, gefitinib was given in combination to standard treatment involving the platinum-containing drugs. Although the other drugs included gemcitabine and cisplatin[29] or paclitaxel and carboplatin,[30] significant combination effects were not obtained.

In 28 countries, not including Japan, a phase III study has been performed for 1692 cases of posttreatment advanced NSCLCs (Iressa Survival Evaluation in Lung Cancer).[31] For either all lung cancers or lung adenocarcinomas, gefitinib (versus placebo) could not significantly prolong survival time for patients. However, on subset analysis, gefitinib did significantly enhance survival in Asian persons and nonsmokers.

SIDE EFFECTS OF EGFR TYROSINE KINASE INHIBITION (GEFITINIB)

Major clinical problems caused by gefitinib are acute lung damage and interstitial pneumonia, the latter being the most significant side effect.[32] An epidemiologic investigation by the West Japan Thoracic Oncology Group, which used approximately 2000 cases, revealed an incidence rate of 3.2% to 3.5% and a death rate of 1.2% to 1.4%. Generally, ineffectiveness of steroid therapy makes the condition serious. Male sex, the existence of lung fibrosis before treatment, and a smoking habit were identified as risk factors for development of interstitial lung diseases related to gefitinib therapy. Thus, the effective treatment group for gefitinib and the high-risk group for interstitial lung disease with gefitinib are widely dissociated. This means that it is essential to preselect patients for gefitinib therapy.

EGFR MUTATIONS AND CLINICOPATHOLOGIC FEATURES

Lung cancers with EGFR mutations are prevalent among patients who are young, of female sex, neversmokers, and of East Asian ethnicity.[2–4,33–35]

Correlations between morphology and EGFR mutations in lung adenocarcinomas have been investigated previously. Concerning histopathology, a bronchioloalveolar carcinoma (BAC) histologic feature and well-differentiated to moderately differentiated grades were earlier reported to predict responsiveness to the EGFR tyrosine kinase (TK) inhibitor and the presence of EGFR mutations[33,34] The finding that the hobnail cell type and a micropapillary morphology can predict a higher incidence of EGFR mutations in lung adenocarcinomas has been reported more recently.[36]

EGFR MUTATIONS AND CELL TYPES IN LUNG ADENOCARCINOMAS

Cell type classification of lung adenocarcinomas was originally performed by Hashimoto et al,[37] describing hobnail, columnar, polygonal, goblet, and mixed cell types. They combined the Clara (nonciliated bronchiolar) cell type and type II cell type as the hobnail cell type because these types have the same cytologic features and are usually found to be mixed. This classification was applied with slight modification to a series of lesions in our hospitals. We divided lung cancers into hobnail, columnar, and polygonal cell types, focusing on the most frequent cell type rather than using the mixed cell category. Also, we merged the goblet and columnar cell types because of similarity in histologic and etiologic features and because the goblet cell type is present in minority (Figure 4, A through C).

As a result, the hobnail cell type was found to be significantly more associated with EGFR mutations than any of the other groups ($P < .001$). The cell type classification also relates to differences in mutation frequency and pattern of *TP53* (which codes for p53 protein).[37] The hobnail cell type, characterized by cytoplasmic protrusions and a tadpole or hobnail appearance, shows a low *TP53* mutational frequency, mainly of spontaneous transition type at CpG nucleotides. In contrast, the columnar cell type shows a high *TP53* mutational frequency, with G to T transversions, considered to be caused by exogenous carcinogenic agents like those found in tobacco smoke. We identified a significant difference in EGFR mutation rates between the hobnail cell type and the other 2 types. This finding provided further evidence of differences in the genetic background of EGFR mutations.

EGFR MUTATIONS AND MICROPAPILLARY PATTERN OR BAC HISTOLOGY IN LUNG ADENOCARCINOMAS

Additionally, we have focused on the presence of BAC component, as well as micropapillary pattern (MPP), defined as papillary structures with tufts lacking a fibrovascular core (Figure 5, A and B).[38] The micropapillary component belongs to moderately differentiated structures because of the lack of stroma.[38] When a cancer comprises more than 5% MPP, the prognosis has been shown to be poor, even with pathologic stage I disease.[38]

As a result, there was a significant association between the existence of BAC component or MPP and EGFR mutations ($P = .01$ and $P = .04$, respectively). In addition, both BAC component and MPP were significantly associated with the hobnail cell type ($P < .001$ and $P = .01$, respectively), as compared with the combined group of columnar and polygonal cell types. However, there was no association between BAC components and MPP ($P = .75$).[36]

The MPP is a distinct pathologic subtype first reported in lung cancers by Amin et al.[39] Among early stage lung adenocarcinomas, MPP-positive cancers show a significantly poorer prognosis than those that are MPP negative.[38] We speculated that the distinct MPP feature reflects a step of tumor progression from well-differentiated papillary adenocarcinoma of the hobnail cell type to a less differentiated state, unrelated to smoking. From their pathologic presentation and relatively unfavorable outcome, it is suggested that cancers with MPP should be classified as moderately differentiated rather than well dif-



Figure 4. *Microscopic appearance of the 3 cytologic subtypes. A, Hobnail cell type. Apical portions of carcinoma cells containing nuclei protrude or bulge into the lumen. B, Columnar cell type. Nonciliated columnar or cuboidal cells, with or without mucus in their cytoplasm, have flat apical portions. C, Polygonal cell type. Note polygonal cells showing sheet-like growth (hematoxylin-eosin, original magnifications ×400).*



Figure 5. *Histologic features of the micropapillary pattern in pulmonary adenocarcinomas. A, Note diffuse distribution of tufts in alveolar spaces. B, Papillary tufts lack central fibrovascular cores (hematoxylin-eosin, original magnifications ×40 [A] and ×400 [B]).*

ferentiated. This pattern is often observed in nonsmokers and correlates with a high degree of tumor aggression. We also have demonstrated that metastasis to lymph nodes, pleural invasion, intrapulmonary metastases, and nonsmoking status are significantly more frequent in MPP-positive cases with a significantly poorer survival.[38] In our study, the presence of MPP components significantly correlated with EGFR mutations. Kim et al[40] referred to an association between the presence of MPP and tumor sensitivity to an EGFR TK inhibitor, although their analysis was limited to 36 relapsed lung adenocarcinomas. A notable characteristic of MPP is its frequent presence at the periphery of cancers and its predominance in metastatic foci.[39,41] These clinicopathologic observations, accompanied by our findings of a high mutational frequency for EGFR, may explain the dramatic responses to gefitinib in lung adenocarcinomas with diffuse micronodular intrapulmonary metastasis.[42]

COMMENT ON EGFR MUTATIONS AND CLINICOPATHOLOGIC FEATURES

Both BAC components and MPP are prevalent among nonsmokers.[38,43] Considering the etiologic relevance and its correlation with EGFR mutations, we speculate that lung cancers with these features belong to the same lineage characterized by thyroid transcription factor–1[35] and the hobnail cell type. Also, the results imply that lesions featuring MPP may be at a slightly more advanced stage than those with BAC components, because the MPP is an adverse prognostic marker for pathologic stage I disease.[38] Lung cancers in nonsmokers are considered to be less genetically complex than those in smokers[44,45] and, therefore, they may have distinct characteristics depending on simple signaling pathways, such as EGFR/Akt, for maintenance and survival.[2] Consequently, patients with tumors harboring these pathologic features could be good candidates and benefit from EGFR TK inhibitors.

CONCLUSION

There is no doubt that the EGFR TK inhibitors and EGFR monoclonal antibodies offer innovative molecular-targeted drugs, effective for some NSCLCs. However, the possibility of acute lung damage and interstitial pneumonia as negative side effects must be borne in mind. Therefore, the fact that in patients who are young, female, never-smokers, and of East Asian ethnicity, one subtype of NSCLC positively responds to EGFR TK inhibitors—because of the presence of EGFR mutations—is of great importance.

Pathologically, the hobnail cell type, MPP, and BAC components of lung adenocarcinomas are associated with a high incidence of EGFR mutations. Adenocarcinomas with these features form a distinct subtype, a fact suggesting that a genetic background confers susceptibility to EGFR TK inhibitors. The immunohistochemical analysis has a potential vulnerability because different antibodies might yield different results. Hence, these histologic features of lung adenocarcinomas with EGFR mutations, which can be detected by hematoxylin-eosin staining, are meaningful. These findings could provide a clue for selection of patients who might benefit from such treatment, as well as insights into biologic mechanisms of phenotype-genotype correlations.

Parts of this study were supported financially by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of the Japan Society for the Promotion of Science and by grants from the Ministry of Health, Labour and Welfare, the Smoking Research Foundation, the National Institute of Biomedical Innovation, and the Vehicle Racing Commemorative Foundation, as well as a Grant-in-Aid for Young Scientists (B).

References

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med.* 2004;350:2129–2139.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science.* 2004;304:1497–1500.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A.* 2004;101:13306–13311.
4. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst.* 2005;97:339–346.
5. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. *Oncogene.* 1991;6:1353–1362.

6. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature.* 2007;448:561–566.
7. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. *Cancer Res.* 2004;64:8919–8923.
8. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. *J Thorac Oncol.* 2008;3:13–17.
9. Carpenter G, Lembach KJ, Morrison MM, Cohen S. Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. *J Biol Chem.* 1975;250:4297–4304.
10. Carpenter G, King L Jr, Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. *Nature.* 1978;276:409–410.
11. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. *Nature.* 1984;307:521–527.
12. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. *Cancer.* 2002;94:1593–1611.
13. Kimura M, Tsuda H, Morita D, et al. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. *Virchows Arch.* 2004;445:255–262.
14. Kimura M, Tsuda H, Morita D, et al. Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. *Jpn J Clin Oncol.* 2005;35:324–331.
15. Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. *Pancreas.* 2004;29:e1–e8.
16. Ueda S, Hatsuse K, Tsuda H, et al. Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. *Mod Pathol.* 2006;19:788–796.
17. Murakawa T, Tsuda H, Tanimoto T, Tanabe T, Kitahara S, Matsubara O. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. *Pathol Int.* 2005;55:757–765.
18. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. *Eur J Cancer.* 2001;37(suppl 4):S9–S15.
19. Yamazaki H, Fukui Y, Ueyama Y, et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. *Mol Cell Biol.* 1988;8:1816–1820.
20. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. *Cell Growth Differ.* 1995;6:1251–1259.
21. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation: biological significance and potential target for anti-cancer therapy. *Ann Oncol.* 2001;12:745–760.
22. Kosaka T, Endoh H, Yatabe Y, Mitsudomi T. Translational research on lung cancer—EGFR gene mutation [in Japanese]. *Gan To Kagaku Ryoho.* 2005;32:750–758.
23. Choi SH, Mendrola JM, Lemmon MA. EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. *Oncogene.* 2007;26:1567–1576.
24. Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. *Cancer Res.* 2005;65:7568–7572.
25. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. *Cancer Cell.* 2006;9:485–495.
26. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. *Clin Cancer Res.* 2006;12:6494–6501.
27. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. *J Clin Oncol.* 2003;21:2237–2246.
28. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA.* 2003;290:2149–2158.
29. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. *J Clin Oncol.* 2004;22:777–784.
30. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. *J Clin Oncol.* 2004;22:785–794.
31. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet.* 2005;366:1527–1537.
32. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. *Lancet.* 2003;361:137–139.
33. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. *J Clin Oncol.* 2004;22:1103–1109.
34. Hsieh RK, Lim KH, Kuo HT, Tzen CY, Huang MJ. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. *Chest.* 2005;128:317–321.
35. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. *Am J Surg Pathol.* 2005;29:633–639.
36. Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas: significance of the micropapillary pattern and the hobnail cell type. *Lung Cancer.* 2009;63:235–240.
37. Hashimoto T, Tokuchi Y, Hayashi M, et al. Different subtypes of human lung adenocarcinoma caused by different etiological factors: evidence from p53 mutational spectra. *Am J Pathol.* 2000;157:2133–2141.
38. Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. *Am J Surg Pathol.* 2003;27:101–109.
39. Amin MB, Tamboli P, Merchant SH, et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. *Am J Surg Pathol.* 2002;26:358–364.
40. Kim YH, Ishii G, Goto K, et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. *Clin Cancer Res.* 2004;10:7311–7317.
41. Makimoto Y, Nabeshima K, Iwasaki H, et al. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (</=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours). *Histopathology.* 2005;46:677–684.
42. Kobayashi M, Takeuchi T, Bandobashi K, et al. Diffuse micronodular pulmonary metastasis of lung adenocarcinoma predicts gefitinib response in association with epidermal growth factor receptor mutations. *Anticancer Res.* 2006;26:1621–1626.
43. Okubo K, Mark EJ, Flieder D, et al. Bronchoalveolar carcinoma: clinical, radiologic, and pathologic factors and survival. *J Thorac Cardiovasc Surg.* 1999;118:702–709.
44. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. *Cancer Res.* 2001;61:1309–1313.
45. Powell CA, Bueno R, Borczuk AC, et al. Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers. *Lung Cancer.* 2003;39:23–29.